Insider · CIK 0001477123
Lloyd Mitchell Segal
Files at RPTX (Repare Therapeutics Inc.), AKTS (Aktis Oncology, Inc.). First filing Mar 27, 2024, latest Apr 1, 2024.
In brief
Lloyd Mitchell Segal files SEC Form 4 as director, CEO and president at RPTX (Repare Therapeutics Inc.), and also at AKTS (Aktis Oncology, Inc.). Since Mar 27, 2024, Lloyd Mitchell Segal has reported 0 open-market buys worth $0 and 2 open-market sells worth $61k, the latest filed on Apr 1, 2024.
A track record needs three past buys with six months of prices behind them; Lloyd Mitchell Segal has 0, so none is measured yet.
The newest scored trade: sold $24k of RPTX on Mar 28, 2024, filed Apr 1, 2024, scored 20 (weak), under a 10b5-1 plan.
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 20Weak | Repare Therapeutics Inc. | $24k 5,141 shares | -5% | - | |
| 26Weak | Repare Therapeutics Inc. | $37k 7,950 shares | -9% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 26, 2024 | RPTX Repare Therapeutics Inc. | 99,466 0.24% of outstanding | $481k | Mar 26, 2024 | none |
| Mar 25, 2024 | RPTX Repare Therapeutics Inc. | 13,091 0.04% of outstanding | $62k | Mar 25, 2024 | none |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Common Stockindirect: See Footnote | +19,631 | - | - | 19,631 | Jan 12, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Series A Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -50,000 | $0.00 | $0 | 0 | Jan 12, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Series B Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -24,687 | $0.00 | $0 | 0 | Jan 12, 2026 |
| Mar 28, 2024 | RPTX Repare Therapeutics Inc. | SOpen-market sale Common Sharesindirect: See footnote10b5-1 | -2,650 | $4.62 | $12k | 110,049 | Apr 1, 2024 |
| Apr 1, 2024 | RPTX Repare Therapeutics Inc. | SOpen-market sale Common Sharesindirect: See footnote10b5-1 | -2,491 | $4.63 | $12k | 107,558 | Apr 1, 2024 |
| Mar 25, 2024 | RPTX Repare Therapeutics Inc. | SOpen-market sale Common Sharesindirect: See footnote10b5-1 | -2,650 | $4.79 | $13k | 89,166 | Mar 27, 2024 |
| Mar 26, 2024 | RPTX Repare Therapeutics Inc. | SOpen-market sale Common Sharesindirect: See footnote10b5-1 | -2,650 | $4.64 | $12k | 86,516 | Mar 27, 2024 |
| Mar 27, 2024 | RPTX Repare Therapeutics Inc. | SOpen-market sale Common Sharesindirect: See footnote10b5-1 | -2,650 | $4.63 | $12k | 83,866 | Mar 27, 2024 |
| Mar 1, 2024 | RPTX Repare Therapeutics Inc. | AGrant or award Common Shares | +40,000 | $0.00 | $0 | 124,677 | Mar 4, 2024 |
| Mar 1, 2024 | RPTX Repare Therapeutics Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +237,000 | $0.00 | $0 | 237,000 | Mar 4, 2024 |
Questions about Lloyd Mitchell Segal
Answered from the filings on this page, as of the latest one.
Is Lloyd Mitchell Segal buying or selling?
Not in the last 12 months. Lloyd Mitchell Segal's latest open-market trade on SEC Form 4 was sold $24k of RPTX on Mar 28, 2024.
How did Lloyd Mitchell Segal's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Lloyd Mitchell Segal has 0.
Where does Lloyd Mitchell Segal file Form 4?
Lloyd Mitchell Segal has filed Form 4 at RPTX (Repare Therapeutics Inc.) as PRESIDENT AND CEO; AKTS (Aktis Oncology, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.